icon

 

With the rest of the market dropping, the news hasn’t been any better for the cancer stocks lately, with the exception of Pharmacyclics (PCYC) last week.. Due in part to the down market and the FDA’s refusal to approve any of the new breed of cancer treatments, the immunotherapy vaccines, th...

Read more